Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:accessories |
various governments
experienced during pandemic |
| gptkbp:activities |
adenoviral vector
|
| gptkbp:approves |
December 2020
multiple countries |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:brand |
gptkb:Vaxzevria
|
| gptkbp:clinical_trial |
multiple countries
over 23,000 Phase III trials Phase I, II, III |
| gptkbp:collaborated_with |
gptkb:University_of_Oxford
|
| gptkbp:communication |
critical for public health
|
| gptkbp:data_type |
published in peer-reviewed journals
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:distribution |
global
|
| gptkbp:dosage_form |
2
recommended after initial doses delivered globally |
| gptkbp:healthcare |
gptkb:significant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca's vaccines
|
| gptkbp:is_effective_against |
around 76%
analyzed regularly |
| gptkbp:is_used_for |
gptkb:COVID-19
|
| gptkbp:is_vulnerable_to |
available online
international ongoing intramuscular injection requires refrigeration cold chain logistics varies by population addressed by campaigns accelerated due to pandemic continues for variants non-replicating viral vector against severe disease monitored by health authorities reduces hospitalization rates conditional in EU |
| gptkbp:manufacturer |
multiple facilities
|
| gptkbp:market |
conducted
|
| gptkbp:partnerships |
gptkb:initiative
|
| gptkbp:public_awareness |
important for uptake
|
| gptkbp:receives_funding_from |
public and private sectors
|
| gptkbp:regulatory_compliance |
gptkb:WHO_Emergency_Use_Listing
|
| gptkbp:safety_features |
ongoing
|
| gptkbp:side_effect |
mild to moderate reactions
|
| gptkbp:supply_chain |
gptkb:launch_complex
|
| gptkbp:target_audience |
adults
|
| gptkbp:type |
viral vector vaccine
|